VEGFA and hepatocellular carcinoma: Ramucirumab, another VEGF monoclonal antibody that was evaluated in second line setting in advanced HCC, showed non-statistically significant favorable results on quality-of-life analyzed by Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8) [31].